Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after neoadjuvant treatment, and FES-PET as potential
暂无分享,去创建一个
Sung-Bae Kim | S. Ahn | H. Lee | J. H. Park | G. Gong | K. Jung | B. Son | Jin-Hee Ahn | H. Kim | D. Moon | J. E. Kim | H. J. Shin | Myung Joo Kang | J. Ahn